Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biontech Se ADR
(NQ:
BNTX
)
120.76
+7.63 (+6.74%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biontech Se ADR
< Previous
1
2
...
16
17
18
19
20
21
22
23
24
...
65
66
Next >
Why BioNTech Was a Sickly Stock This Week
December 30, 2022
The world is trying hard to get past the coronavirus pandemic, and investors are trying hard to get past coronavirus stocks.
Via
The Motley Fool
BioNTech to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 28, 2022
From
BioNTech SE
Via
GlobeNewswire
Three Pharma Stocks to Sell Before They Die
December 24, 2022
As we head into New Year 2023, these are just some of the top pharma stocks to sell at the start of January.
Via
InvestorPlace
BioNTech Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165
December 23, 2022
From
BioNTech SE
Via
GlobeNewswire
BioNTech Starts Dosing In Herpes Vaccine Candidate Study
December 21, 2022
Via
Benzinga
Will Investors Notice Exciting Sign On BioNTech's Chart?
December 19, 2022
Via
Benzinga
BioNTech and Fosun Pharma Provide COVID-19 Vaccine Doses For Vaccination of German Expatriates in China
December 22, 2022
From
BioNTech SE
Via
GlobeNewswire
Update on First BioNTainer for African-based mRNA Manufacturing Facility
December 21, 2022
From
BioNTech SE
Via
GlobeNewswire
BioNTech, Ryvu Therapeutics Join Forces For Immuno-Modulatory Candidates
November 30, 2022
Via
Benzinga
BioNTech Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163
December 21, 2022
From
BioNTech SE
Via
GlobeNewswire
The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond
December 18, 2022
These seven hottest healthcare stocks have strong growth catalysts that could send each of them higher over the next few years.
Via
InvestorPlace
Market Rally Pressured On Fed Rate Outlook; Moderna, Boeing, Tesla In Focus: Weekly Review
December 16, 2022
Moderna spiked on a cancer vaccine while Tesla continued to dive.
Via
Investor's Business Daily
BioNTech Stock Gets Upgrade, Analyst Sees Multiple Upside Opportunities
December 15, 2022
Via
Benzinga
Why Is Novavax (NVAX) Stock Plunging Today?
December 15, 2022
NVAX stock is down today on fundraising plans. Here's what investors should know about this once-promising Covid-19 vaccine player.
Via
InvestorPlace
Pfizer Expects $10-$15B From mRNA Vaccine Sales By 2030, Sees $17B Revenues Lost Due To Patent Expiry
December 13, 2022
At Pipeline Day, Pfizer Inc (NYSE: PFE) forecasts annual revenue from its mRNA vaccine portfolio could reach $10-$15 billion by 2030.
Via
Benzinga
Why Merck's $250 Million Investment In Moderna May Have Just Paid Off
December 13, 2022
Merck opted into Moderna's cancer vaccine. Now, the companies have Phase 2 data.
Via
Investor's Business Daily
Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza
December 09, 2022
From
BioNTech SE
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2022
December 15, 2022
Via
Benzinga
FDA Authorizes Pfizer/BioNTech And Moderna's Bivalent COVID Shots For 6 Months Old
December 08, 2022
Via
Benzinga
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years
December 08, 2022
From
Pfizer Inc.
Via
Business Wire
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years
December 08, 2022
From
BioNTech SE
Via
GlobeNewswire
US Supports Delay On COVID Patent Waiver Extension Decision
December 06, 2022
Developing countries have been pushing for a patent waiver extension for COVID-19, which many developed countries argue could discourage pharma companies from responding rapidly to future global health...
Via
Benzinga
UK's Regulatory Agency Backs Pfizer/BioNTech's COVID-19 Vaccine For Youngest Kids
December 06, 2022
Via
Benzinga
Pfizer, BioNTech Fire Back At Moderna Over COVID-19 Vaccine Related Patent Claims
December 06, 2022
Via
Benzinga
BioNTech, Vertex Pharmaceuticals And Other Big Biotechnology Stocks From Benzinga's Most Accurate Analysts
December 02, 2022
Although US stocks closed mixed on Thursday, but healthcare stocks recorded gains, gaining over 0.2% in the previous session. Biotechnology stocks were among the top performers in the sector, adding...
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
December 01, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
BioNTech and Ryvu Therapeutics Enter into Global Collaboration to Develop and Commercialize Immuno-Modulatory Small Molecule Candidates
November 30, 2022
From
BioNTech SE
Via
GlobeNewswire
2 Biotech Stocks You Can Buy and Hold for the Next Decade
November 28, 2022
These two companies are facing short-term issues that are likely to give way to long-term success.
Via
The Motley Fool
Is Novavax Stock a Buy Now?
November 26, 2022
There's probably not much good news coming for this biotech in the near future.
Via
The Motley Fool
European Official Says COVID-19 Booster Uptake Disappointing In The Region
November 25, 2022
Marco Cavaleri, the European Medicines Agency's (EMA) head of health threats and vaccines strategy, said the recent uptake of COVID-19 vaccine booster doses in the region has been "rather...
Via
Benzinga
< Previous
1
2
...
16
17
18
19
20
21
22
23
24
...
65
66
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.